which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months (12 or 16 weeks) compared to standard of care Eylea 2 mg (aflibercept 2 mg) with a fixed ...

Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label extension for ...

Aflibercept 2 mg (Eylea, Bayer AG) injections were administered using a prefilled syringe (PFS), following the manufacturer’s indications, with a 30-gauge needle and injecting 0.05 mL of medication (2 ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

Eylea 8 mg continued to demonstrate a favorable safety profile in the third year, consistent with the well-established safety profile of Eylea 2 mg. Long-term safety data revealed no new safety ...

Eylea 8 mg continued to demonstrate a favorable safety profile in the third year, consistent with the well-established safety profile of Eylea 2 mg. Long-term safety data revealed no new safety ...

Eylea 8 mg is already approved in more than 50 markets, and further regulatory submissions are under review in additional countries. In the EU and U.K., Eylea 8 mg is the only anti-VEGF treatment ...

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected ... Bayer shares were up 2.5% at 0717 GMT, surpassing a gain ...

In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...

In terms of study design itself, the PULSAR trial recruited treatment-naive patients with neovascular AMD, and these patients were randomly assigned 1:1:1 to EYLEA 2 mg given every 8 weeks, EYLEA 8 mg ...